Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer

By Brian Bierie, H. Moses. Nature Reviews. Cancer, 2006

1,340 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

TGFβ in Cancer (2008, background): “…apply to targeting a pleiotropic cytokine pathway, antiTGFβ compounds have been developed that show efficacy in preclinical studies, and clinical trials with several of these compounds are underway (for more detailed commentaries, see Arteaga, 2006; Bierie and Moses, 2006; Wrzesinski et al., 2007).”
Hallmarks of cancer: the next generation. (2011, positive): “TGF-b is best known for its antiproliferative effects, and evasion by cancer cells of these effects is now appreciated to be far more elaborate than simple shutdown of its signaling circuitry (Ikush-ima and Miyazono, 2010; Massague´, 2008; Bierie and Moses, 2006).”
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin signaling (2009, background): “TGFb in turn regulates the expression of many ECM proteins and modifying enzymes including LOXs, and TGFb increases levels of factors that evoke inflammation, induce fibrosis and promote metastasis (Bierie and Moses, 2006; Oleggini et al., 2007).”